Neurology

EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out  Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer’s Disease. Eisai will through a one-time payment to Purdue, will make Purdue no longer a participant or fund-raiser for the development and commercialization of lemborexant. Keytruda contributes to Merck’s fortune A steep increase in ...